The HDL hypothesis: do recent trials with niacin add anything?
A position statement from HDL Forum Editor, Professor Philip Barter
HDL risk markers in secondary prevention.
Professor John Chapman, Past-President of the European Atherosclerosis Society, INSERM, Hôpital de la Pitié, Paris, France:
'Inflammation is a critical parameter in modifying the lipidome and proteome of HDL. Crucially, these changes are not revealed by measurement of HDL cholesterol concentration. There is clearly tremendous potential for new information on alternative biomarkers in patients with coronary artery disease from cohorts such as LURIC.'Read the full report here